Search Results - Oncology

15 Results

Sort By:

Monoclonal Antibodies Against PCDH7 for Therapeutic and Diagnostic Use

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-associated deaths worldwide. UTHealth researchers discovered that the cell surface protein Protocadherin 7 (PCDH7) is highly expressed in NSCLC and promotes lung cancer development. Inventors at UTH in collaboration with Dr. O’Donnell’s group at UTSW have discovered a panel...

Published: 3/21/2024 | Inventor(s):

Keywords(s):

Category(s): Diagnostics, Oncology, Therapeutics

Monoclonal antibodies against human endotrophin for therapeutic and diagnostic use.

Background Studies have shown that endotrophin, the carboxy-terminal cleavage product of the COL6α3 chain, has potent effects on transformed mammary ductal epithelial cells in rodents. It is abundantly expressed in adipose tissue and is a chemoattractant for macrophages, exerts effects on endothelial cells and enhances the progression through...

Published: 2/8/2024 | Inventor(s): Zhiqiang An, Ningyan Zhang, Philipp Scherer

Keywords(s):

Category(s): Biologics, Oncology, Therapeutics

TREM2 Monoclonal Antibody for Therapeutic and Diagnostic Use

Triggering Receptor Expressed on Myeloid cells 2 (TREM2) plays a key regulatory role in Alzheimer’s disease (AD) by controlling microglia activation and metabolic activities in brain tissues. Previous studies in rodent models of AD have shown that mice with increased TREM2 expression have reduced amyloid pathology. UTHealth inventors created and...

Published: 12/19/2023 | Inventor(s): Zhiqiang An

Keywords(s):

Category(s): Therapeutics, Oncology, Diagnostics

LGR4 Specific Monoclonal Antibodies and Their Use

Researchers at UTHealth have isolated and characterized monoclonal antibodies as well as antibody fragments that specifically binding to LGR4, a 7TM receptor that is highly expressed in major types of solid tumors, including but not limited to colorectal cancer, non-small cell lung cancer, and ovarian cancer. These LGR4 specific monoclonal antibodies...

Published: 8/15/2023 | Inventor(s): Qingyun (Jim) Liu

Keywords(s):

Category(s): Biologics, Oncology, Therapeutics, Diagnostics, Research Materials

Mutants and Drug Conjugates of R-Spondin Polypeptides for Cancer Therapy

R-spondins (RSPOs) are secreted proteins with critical roles in cancer development through binding to LGRs and RNF43/ZNRF3 and potentiating Wnt signaling. Various RSPO mutants were discovered that bind to LGRs but no longer function in Wnt signaling. Fc fusion protein of the RSPO mutants, so called RSPO peptibodies, were conjugated with cytotoxic...

Published: 8/15/2023 | Inventor(s): Qingyun (Jim) Liu

Keywords(s):

Category(s): Biologics, Oncology, Therapeutics

Novel Oncolytic Herpes Simplex Virus (oHSV) for Cancer Treatment

Researchers from UTHealth have developed a novel oncolytic viral therapy, oHSV-shPKR, which can inhibit tumor cells’ antiviral PKR activity, and increase oncolytic virus infection and replication in both oncolytic viral-resistant and sensitive cancer cells. This novel oHSV-shPKR therapy can significantly increase the anti-tumor immune response...

Published: 8/15/2023 | Inventor(s): Balveen Kaur, BangXing Hong

Keywords(s):

Category(s): Biologics, Oncology, Therapeutics

Co-Administration of Oncolytic Herpes Simplex Virus (oHSV) with Cisplatin for Anti-Cancer Immunotherapy

Researchers from UTHealth and Ohio State University College of Medicine have collaborated to investigate the impact of oHSV therapy in combination with platinum agents using platinum-resistant high-grade serous ovarian carcinoma (HGSOC) as well as platinum-resistant ovarian clear cell carcinoma models. More importantly, they have developed a novel...

Published: 8/15/2023 | Inventor(s): Balveen Kaur

Keywords(s):

Category(s): Therapeutics, Oncology

Monoclonal Antibodies Against Oncostatin M Receptor (OSMR) for Therapeutic and Diagnostic Use

Researchers from UTHealth and The Medical College of Wisconsin have collaborated to reveal the role of OSMR in promoting ovarian cancer cell proliferation and metastasis through activation of STAT3 signaling, as well as illuminated the preclinical efficacy of antibody-based OSMR targeting for ovarian cancer treatment. More particularly, researchers...

Published: 9/27/2023 | Inventor(s): Zhiqiang An

Keywords(s):

Category(s): Diagnostics, Therapeutics, Biologics, Oncology

Peptides Targeting Chemotherapy-Resistant Metastatic Cancer Cells for Therapeutic and Diagnostic Use

Researchers at UTHealth have identified new molecules that selectively target metastatic cancer cells in mammals both in vitro and in vivo by screening a combinatorial library in a mouse mammary tumor model of spontaneous metastasis, and demonstrated their application as noninvasive imaging probes and vehicles for cytotoxic therapy delivery in preclinical...

Published: 3/26/2024 | Inventor(s): Mikhail Kolonin

Keywords(s):

Category(s): Oncology, Therapeutics, Diagnostics

Monoclonal Antibodies Against Chitinase 3-like-1 (Chi3l1) for Therapeutic and Diagnostic Use

Researchers at UTHealth have unveiled a critical role of Chi3l1 in hepatic platelet recruitment during acetaminophen (APAP)-induced liver injury (AILI) using murine models of AILI and concanavalin A (Con A)-induced hepatitis. Significantly, they have developed anti-Chi3l1 monoclonal antibodies and demonstrated the feasibility of targeting CHI3L1...

Published: 8/15/2023 | Inventor(s): Zhiqiang An, Changqing (Cynthia) Ju

Keywords(s):

Category(s): Biologics, Therapeutics, Oncology

1 2